Serum-Free Hypothermic Blood Preservation Solution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for hypothermic storage of blood have limited effectiveness in maintaining the quality and viability of blood cells, leading to issues such as increased cell death, infections, and reduced transfusion efficacy due to inadequate preservation techniques.
Innovation Solution
The use of a serum-free, protein-free hypothermic preservation solution like HYPOTHERMOSOL, which reduces free radical accumulation and osmotic stress, combined with a cryopreservation solution like CRYOSTOR, to create an optimal environment for hypothermic and cryogenic storage, enhancing cell viability and functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If conventional hypothermic storage methods are used, then storage duration is extended, but cell viability and quality deteriorate due to free radical accumulation and osmotic stress
Solution Approach 1:
The patent changes the chemical composition parameters of the storage solution by incorporating specific antioxidants (methylprednisolone, ascorbic acid, glutathione) and osmotic agents (mannitol, sorbitol) at optimized concentrations. This modifies the biochemical environment to reduce free radical accumulation and osmotic stress, thereby maintaining cell viability during extended hypothermic storage periods
Solution Approach 2:
The patent introduces intermediary substances (antioxidants and osmotic agents) that mediate between the hypothermic storage conditions and the blood cells. These intermediaries protect cells from the harmful effects of cold storage by scavenging free radicals and maintaining osmotic balance, thus preserving cell viability throughout the storage duration
2Reliability
If serum or proteins are added to preservation solution, then cell viability improves, but risk of xenographic biologic transmission and cytotoxicity increases
Solution Approach 1:
The patent extracts and eliminates serum and proteins from the preservation solution formulation. By removing these biological components, the patent eliminates the associated risks of xenographic biologic transmission and cytotoxicity while maintaining cell viability through alternative protective mechanisms (antioxidants and osmotic agents)
Solution Approach 2:
The patent replaces complex, risky biological components (serum, proteins) with simpler, safer chemical compounds (antioxidants, osmotic agents). These synthetic or semi-synthetic substances provide the necessary protective functions without the biological risks associated with serum-based solutions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces cell death during storage, maintains cell viability and functionality, and allows for extended storage times without the need for serum or high levels of cytotoxic agents, improving the quality and safety of blood products.
Implementation Method 1
Any preservation solution which is formulated to reduce free radical accumulation in cells undergoing hypothermic preservation to help mediate the level of post-storage necrosis and apoptosis
Implementation Method 2
a preservation solution adapted for cellular osmotic balance at hypothermic temperatures
Implementation Method 3
long-term frozen storage of isolated cellular components is performed using a cryopreservation solution formulated to address the molecular-biological aspects of cells during the cryopreservation process
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to materials and methods for hypothermic collection of whole blood, and components thereof, which can extend the holding time of blood beyond the current useable limit. Additionally, blood can be drawn directly into a hypothermic preservation solution without the addition of standard anticoagulants. This is enabled by providing sustained cellular viability under hypothermic conditions using a nutrient matrix devoid of animal proteins and containing energy substrates, free-radical scavengers, and impermeants that is ionically balanced for storage of biologic materials at low temperatures to prevent cellular stress-induced apoptosis.